On April 12, AVAC and FP2030 convened a consultation with family planning (FP) and sexual and reproductive health (SRH) stakeholders to understand their unique perspectives on the Dual Prevention Pill (DPP), a daily pill that prevents HIV and pregnancy. The consultation focused on key issues that must inform plans for DPP introduction plans and the development and delivery of future multi-purpose prevention technologies (MPTs).
- Jessica Rodrigues (AVAC) presented an overview of the DPP in the context of MPTs and highlighted progress to date and key milestones for research and development, evidence generation and market preparation
- Barbara Friedland (Population Council) outlined key questions and complexities on potential demand for DPP, the DPP in the FP landscape and aligning PrEP & COC counseling guidance
- Danny Edwards and Dani Resar (CHAI) discussed systems considerations for DPP (and future MPT) introduction, with a focus on procurement of the DPP by FP agencies/organizations and adaptations needed to support M&E planning for the DPP
- Beth Fredrick (Johns Hopkins Bloomberg School of Public Health) facilitated a discussion featuring audience perspectives on potential opportunities and challenges for the DPP
- Mande Limbu and Hima Patel (FP2030) opened and closed the webinar